CUE just had its biggest week in recent memory — and the catalyst wasn't a trial readout.
The small-cap biotech announced a $30 million private placement, licensed a clinical-stage dual-mechanism anti-IgE antibody (Ascendant-221) from Ascendant Health Sciences in a deal valued up to roughly $691.5 million, and named Shao-Lee Lin M.D., Ph.D. as its new CEO, President, and Board Director — all in the same overnight press wave on April 30 into May 1. The stock responded violently. CUE closed at $30.42 on May 1, up 106% on the day alone and 72% for the week. Over the past month, the shares are up 341%, from a base that sat well below $10.
The short-squeeze dynamic is the sharpest feature of the positioning picture. Short interest collapsed 81% over the past week to just 1.1% of the free float — roughly 877,000 shares — after sitting near 7 million shares as recently as mid-April. That unwinding happened into a rising stock: latecomers covering into the rally drove the price higher, not fundamental demand alone. What makes the lending market notable is that availability has simultaneously tightened to its most constrained level in over a year. The borrow pool is almost entirely depleted, with availability at the 52-week floor. Cost to borrow, which was running below 2% in late March, jumped to a peak of 37% intraday in mid-April before settling back to around 12.6% — still ten times its March levels. The combination of nearly exhausted supply and a much smaller remaining short base is an unusual setup: the obvious squeeze fuel has already burned, but what's left is expensive to maintain.
Options traders lean firmly toward the upside. The put/call ratio dropped to 0.091 on May 1 — well below its 20-day average of 0.107 and close to the lowest level of the past 52 weeks. Calls dominate the book by a wide margin. That skew reflects the news-driven momentum rather than hedged positioning; there is no meaningful defensive overhang in the options market to counterbalance the price move.
The Street angle is sparse but relevant. The lone price target on record is $115.00, well above the current close — though the absence of recent analyst changes means the target pre-dates the company's transformation and should be treated as context rather than a current directional signal. The ORTEX short score sits at 73.2, down from a spike near 85.7 on April 23 when the squeeze was at its most acute. That partial retreat in the short score reflects the rapid cover of exposed shorts, not a fundamental re-rating. An S-8 filing on May 1 — registering new equity compensation shares — signals the company is already positioning for a larger headcount following the CEO hire and pipeline expansion.
Earnings land on May 13. The last two prints saw the stock fall 10–13% on the announcement day before recovering sharply over the following week in one instance (+69% five-day move after the April 13 event). With the stock now trading at multi-year highs and a newly licensed asset not yet in trials, the May 13 call is less about pipeline milestones and more about how management articulates the capital deployment plan behind the $30 million raise and the Ascendant deal's milestone structure.
Correlated Nasdaq peers PDSB and SILO were largely flat to modestly up on the week — gains of 9% and losses of 9% respectively — underscoring that this week's move was entirely CUE-specific rather than a sector-wide bid. What to watch next is how the borrow market evolves into the May 13 earnings date: if availability tightens further from here, the remaining short interest — small as it is — faces real friction at a pivotal catalyst.
See the live data behind this article on ORTEX.
Open CUE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
